Literature DB >> 20181896

Association of schistosomiasis with false-positive HIV test results in an African adolescent population.

Dean B Everett1, Kathy J Baisely, Ruth McNerney, Ian Hambleton, Tobias Chirwa, David A Ross, John Changalucha, Deborah Watson-Jones, Helena Helmby, David W Dunne, David Mabey, Richard J Hayes.   

Abstract

This study was designed to investigate the factors associated with the high rate of false-positive test results observed with the 4th-generation Murex HIV Ag/Ab Combination EIA (enzyme immunoassay) within an adolescent and young-adult cohort in northwest Tanzania. (4th-generation assays by definition detect both HIV antigen and antibody.) The clinical and sociodemographic factors associated with false-positive HIV results were analyzed for 6,940 Tanzanian adolescents and young adults. A subsample of 284 Murex assay-negative and 240 false-positive serum samples were analyzed for immunological factors, including IgG antibodies to malaria and schistosoma parasites, heterophile antibodies, and rheumatoid factor (RF) titers. Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). False-positive HIV test results were associated with evidence of other infections. False positivity was strongly associated with increasing levels of Schistosoma haematobium worm IgG1, with adolescents with optical densities in the top quartile being at the highest risk (adjusted OR=40.7, 95% CI=8.5 to 194.2 compared with the risk for those in the bottom quartile). False positivity was also significantly associated with increasing S. mansoni egg IgG1 titers and RF titers of >or=80 (adjusted OR=8.2, 95% CI=2.8 to 24.3). There was a significant negative association between Murex assay false positivity and the levels of S. mansoni worm IgG1 and IgG2 and Plasmodium falciparum IgG1 and IgG4. In Africa, endemic infections may affect the specificities of immunoassays for HIV infection. Caution should be used when the results of 4th-generation HIV test results are interpreted for African adolescent populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181896      PMCID: PMC2863920          DOI: 10.1128/JCM.02264-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Improved performance of seroconversion with a 4th generation HIV antigen/antibody assay.

Authors:  J van Binsbergen; A Siebelink; A Jacobs; W Keur; F Bruynis; M van de Graaf; J van der Heijden; D Kambel; J Toonen
Journal:  J Virol Methods       Date:  1999-09       Impact factor: 2.014

2.  Community's willingness to pay for a school-based chemotherapy programme to control morbidity due to schistosomiasis and soil-transmitted helminthiasis in children in rural Tanzania.

Authors:  N J S Lwambo; J E Siza; G C Mwenda
Journal:  Tanzan Health Res Bull       Date:  2005-09

Review 3.  Laboratory diagnosis of HIV-1 and HIV-2 in Africa.

Authors:  S M'Boup; P J Kanki; F S Mhalu
Journal:  AIDS       Date:  1991       Impact factor: 4.177

4.  Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study.

Authors:  Ronald H Gray; Fredrick Makumbi; David Serwadda; Tom Lutalo; Fred Nalugoda; Pius Opendi; Godfrey Kigozi; Steven J Reynolds; Nelson K Sewankambo; Maria J Wawer
Journal:  BMJ       Date:  2007-06-01

5.  False-positive rapid tests for malaria in patients with rheumatoid factor.

Authors:  M P Grobusch; U Alpermann; S Schwenke; T Jelinek; D C Warhurst
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

6.  Identification and partial purification of an antigen (omega 1) from Schistosoma mansoni eggs which is putatively hepatotoxic in T-cell deprived mice.

Authors:  D W Dunne; S Lucas; Q Bickle; S Pearson; L Madgwick; J Bain; M J Doenhoff
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

7.  Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection.

Authors:  D W Dunne; A E Butterworth; A J Fulford; H C Kariuki; J G Langley; J H Ouma; A Capron; R J Pierce; R F Sturrock
Journal:  Eur J Immunol       Date:  1992-06       Impact factor: 5.532

8.  Epidemiological and genetic aspects of IgM rheumatoid factors.

Authors:  G Husby; J T Gran; A Johannessen
Journal:  Scand J Rheumatol Suppl       Date:  1988

9.  Specificity of IgM antiglobulins produced in rheumatoid arthritis and tropical infections.

Authors:  A O Adebajo; T E Cawston; B L Hazleman
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

10.  Biological and behavioural impact of an adolescent sexual health intervention in Tanzania: a community-randomized trial.

Authors:  David A Ross; John Changalucha; Angela In Obasi; Jim Todd; Mary L Plummer; Bernadette Cleophas-Mazige; Alessandra Anemona; Dean Everett; Helen A Weiss; David C Mabey; Heiner Grosskurth; Richard J Hayes
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

View more
  27 in total

1.  Acute Dengue fever causes false-positive reactivity in OraQuick rapid HIV-1/2 antibody test.

Authors:  Alice Mao; Chidera Obi-Gwacham; Tamsey Hill; Catherine Ryan; Arthur Hendricks; Mehri McKellar
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

2.  Determination of HIV Status in African Adults With Discordant HIV Rapid Tests.

Authors:  Jessica M Fogel; Estelle Piwowar-Manning; Kelsey Donohue; Vanessa Cummings; Mark A Marzinke; William Clarke; Autumn Breaud; Agnès Fiamma; Deborah Donnell; Michal Kulich; Jessie K K Mbwambo; Linda Richter; Glenda Gray; Michael Sweat; Thomas J Coates; Susan H Eshleman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-08-01       Impact factor: 3.731

3.  Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial.

Authors:  Tania Crucitti; Doug Taylor; Greet Beelaert; Katrien Fransen; Lut Van Damme
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

4.  Low specificities of HIV diagnostic tests caused by Trypanosoma brucei gambiense sleeping sickness.

Authors:  V Lejon; D Mumba Ngoyi; M Ilunga; G Beelaert; I Maes; P Büscher; K Fransen
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

5.  A case study of human immunodeficiency virus with positive seroconversion to negative.

Authors:  V Paranthaman; H L Yip; H B Ker
Journal:  Malays Fam Physician       Date:  2015-04-30

6.  Screening for hepatitis C virus infection in a high prevalence country by an antigen/antibody combination assay versus a rapid test.

Authors:  Claude Tayou Tagny; Dora Mbanya; Edward L Murphy; Jean-Jacques Lefrère; Syria Laperche
Journal:  J Virol Methods       Date:  2014-01-30       Impact factor: 2.014

7.  Molecular and immunological characterization of cathepsin L-like cysteine protease of Paragonimus pseudoheterotremus.

Authors:  Tippayarat Yoonuan; Supaporn Nuamtanong; Paron Dekumyoy; Orawan Phuphisut; Poom Adisakwattana
Journal:  Parasitol Res       Date:  2016-08-26       Impact factor: 2.289

8.  Association of inconclusive sera for human immunodeficiency virus infection with malaria and Epstein-Barr virus infection in Central Africa.

Authors:  Francois-Xavier Mbopi-Keou; Angélique Ndjoyi-Mbiguino; Frédéric Talla; Hélène Péré; Khady Kebe; Mathieu Matta; Maurice Aurelien Sosso; Laurent Bélec
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

9.  The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301).

Authors:  Ute Jentsch; Precious Lunga; Charles Lacey; Jonathan Weber; Janet Cairns; Gisela Pinheiro; Sarah Joseph; Wendy Stevens; Sheena McCormack
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

10.  False positive HIV diagnoses in resource limited settings: operational lessons learned for HIV programmes.

Authors:  Leslie Shanks; Derryck Klarkowski; Daniel P O'Brien
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.